NASDAQ:OVID - Ovid Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $14.00
  • Forecasted Upside: 128.76 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$6.12
+0.30 (1.20%)
1 month | 3 months | 12 months
Get New Ovid Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OVID and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OVID

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$14.00
▲ +128.76% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Ovid Therapeutics in the last 3 months. The average price target is $14.00, with a high forecast of $21.00 and a low forecast of $10.00. The average price target represents a 128.76% upside from the last price of $6.12.
Buy
The current consensus among 6 contributing investment analysts is to buy stock in Ovid Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/4/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/2/2019
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/1/2019
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/29/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/29/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/27/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/25/2020

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/19/2020Royal Bank of CanadaReiterated RatingBuy$17.00Low
i
10/2/2020William BlairReiterated RatingBuyLow
i
8/26/2020Cantor FitzgeraldLower Price Target$13.00 ➝ $12.00High
i
8/26/2020Royal Bank of CanadaBoost Price TargetOutperform$13.00 ➝ $17.00High
i
8/26/2020CitigroupBoost Price TargetIn-Line ➝ Buy$9.00 ➝ $10.00Medium
i
8/11/2020William BlairReiterated RatingBuyMedium
i
Rating by T. Lugo at William Blair
7/26/2020Royal Bank of CanadaReiterated RatingBuy$13.00Low
i
7/17/2020William BlairReiterated RatingBuyLow
i
Rating by T. Lugo at William Blair
7/14/2020CitigroupBoost Price TargetBuy$8.00 ➝ $9.00Medium
i
7/13/2020LADENBURG THALM/SH SHReiterated RatingBuy$21.00High
i
6/21/2020Royal Bank of CanadaReiterated RatingBuy$13.00Low
i
6/18/2020Piper SandlerReiterated RatingOverweight$10.00High
i
6/18/2020LADENBURG THALM/SH SHReiterated RatingBuy$20.00High
i
6/18/2020Cantor FitzgeraldBoost Price TargetOverweight$7.00 ➝ $13.00High
i
3/11/2020William BlairReiterated RatingOutperformHigh
i
Rating by T. Lugo at William Blair
3/6/2020LADENBURG THALM/SH SHReiterated RatingBuy$20.00High
i
11/22/2019William BlairReiterated RatingBuyLow
i
11/11/2019CowenReiterated RatingBuyLow
i
9/24/2019CitigroupBoost Price TargetBuy$8.00 ➝ $10.00High
i
9/23/2019Piper Jaffray CompaniesSet Price TargetBuy$14.00Medium
i
Rating by Tyler Van Buren at Piper Jaffray Companies
9/4/2019Royal Bank of CanadaInitiated CoverageOutperform$12.00High
i
7/1/2019CowenReiterated RatingBuyHigh
i
5/16/2019LADENBURG THALM/SH SHReiterated RatingBuy$27.00High
i
Rating by Michael Higgins at LADENBURG THALM/SH SH
5/12/2019CowenReiterated RatingBuyLow
i
3/10/2019Piper Jaffray CompaniesLower Price TargetOverweight$14.00Low
i
3/8/2019LADENBURG THALM/SH SHSet Price TargetBuy$27.00Low
i
Rating by Michael Higgins at LADENBURG THALM/SH SH
3/8/2019JMP SecuritiesLower Price TargetOutperform$26.00 ➝ $11.00Medium
i
12/17/2018Cantor FitzgeraldSet Price TargetBuy$10.00Medium
i
Rating by Charles Duncan at Cantor Fitzgerald
12/6/2018Cantor FitzgeraldReiterated RatingBuy$10.00Medium
i
Rating by Charles Duncan at Cantor Fitzgerald
11/14/2018Cantor FitzgeraldInitiated CoverageOverweightMedium
i
Rating by C. Duncan at Cantor Fitzgerald
8/12/2018Piper Jaffray CompaniesSet Price TargetBuy$20.00Low
i
Rating by Tyler Van Buren at Piper Jaffray Companies
8/6/2018Piper Jaffray CompaniesSet Price TargetBuy$20.00High
i
Rating by Tyler Van Buren at Piper Jaffray Companies
5/20/2018Piper Jaffray CompaniesInitiated CoverageBuy$20.00High
i
Rating by Tyler Van Buren at Piper Jaffray Companies
4/20/2018LADENBURG THALM/SH SHInitiated CoverageBuy$27.00Medium
i
4/1/2018CowenReiterated RatingBuyHigh
i
3/9/2018Piper Jaffray CompaniesInitiated CoverageOverweight$20.00High
i
5/30/2017CitigroupInitiated CoverageBuy ➝ Buy$21.00High
i
5/30/2017William BlairInitiated CoverageOutperform ➝ OutperformHigh
i
Rating by T. Lugo at William Blair
5/30/2017JMP SecuritiesInitiated CoverageMkt Outperform ➝ Outperform$26.00High
i
5/30/2017CowenInitiated CoverageOutperformHigh
i
(Data available from 11/25/2015 forward)
Ovid Therapeutics logo
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase III clinical trial for the treatment of angelman syndrome in adults; and completed Phase II clinical trial for the treatment of fragile X syndrome in adolescent and young male adults. It is also developing OV935, a drug candidate, which is in a Phase II clinical trial for the treatment of cyclin-dependent kinase-like 5 deficiency disorder and dravet syndrome. In addition, the company undertakes research programs exploring OV329 in infantile spasm/rare epilepsies; and OV881 as a microRNA gene therapy for the treatment of angelman syndrome. Ovid Therapeutics Inc. has a collaboration agreement with Takeda Pharmaceutical Company Limited; a license agreement with H. Lundbeck A/S; strategic research collaboration with Columbia University Irving Medical Center; and license agreement with Angelini Pharma to develop, manufacture and commercialize OV101 for the treatment of angelman syndrome in Europe. The company was founded in 2014 and is headquartered in New York, New York.
Read More

Today's Range

Now: $6.12
$6.00
$6.29

50 Day Range

MA: $5.55
$4.94
$6.17

52 Week Range

Now: $6.12
$1.80
$9.40

Volume

537,867 shs

Average Volume

948,522 shs

Market Capitalization

$388.22 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.89